{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:38:37Z","timestamp":1784543917013,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004360"],"award-info":[{"award-number":["UM1TR004360"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA053507"],"award-info":[{"award-number":["K23DA053507"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA050207"],"award-info":[{"award-number":["UG1DA050207"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.dadr.2024.100304","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:17:29Z","timestamp":1732295849000},"page":"100304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Phase 1b\/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial"],"prefix":"10.1016","volume":"14","author":[{"given":"Caitlin E.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Bjork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Keyser-Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T.","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pignatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameron","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Gerard","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dadr.2024.100304_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.dadr.2024.100304_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-3999(97)00298-5","article-title":"Psychometric evaluation of the Pittsburgh Sleep Quality Index","volume":"45","author":"Carpenter","year":"1998","journal-title":"J. Psychosom. Res"},{"issue":"1","key":"10.1016\/j.dadr.2024.100304_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5664\/jcsm.10788","article-title":"A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea","volume":"20","author":"Cheng","year":"2024","journal-title":"J. Clin. Sleep. Med"},{"issue":"7","key":"10.1016\/j.dadr.2024.100304_bib4","article-title":"Correlation of various sleep patterns on different types of memory retention: a systematic review","volume":"15","author":"Dahat","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.dadr.2024.100304_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pnpbp.2015.01.009","article-title":"Evaluation of the dopamine \u03b2-hydroxylase (D\u03b2H) inhibitor nepicastat in participants who meet criteria for cocaine use disorder","volume":"59","author":"De La Garza","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.dadr.2024.100304_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.addbeh.2017.07.016","article-title":"Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients","volume":"76","author":"Dunn","year":"2018","journal-title":"Addict. Behav."},{"issue":"4","key":"10.1016\/j.dadr.2024.100304_bib7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/mol.119.119107","article-title":"Bidirectional relationship between opioids and disrupted sleep: putative mechanisms","volume":"98","author":"Eacret","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.dadr.2024.100304_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1244156","article-title":"Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder [Brief Research Report]","volume":"14","author":"Eglovitch","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.dadr.2024.100304_bib9","unstructured":"FDA. (2020). DAYVIGO (lemborexant) PRESCRIBING INFORMATION. FDA. Retrieved April from \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-dayvigo\u3009"},{"issue":"3","key":"10.1016\/j.dadr.2024.100304_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12946","article-title":"Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system","volume":"26","author":"Fragale","year":"2021","journal-title":"Addict. Biol."},{"key":"10.1016\/j.dadr.2024.100304_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000514965","article-title":"The insomnia-addiction positive feedback loop: role of the orexin system","volume":"45","author":"Fragale","year":"2021","journal-title":"Front Neurol. Neurosci."},{"key":"10.1016\/j.dadr.2024.100304_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.07.026","article-title":"The contribution of orexins to sex differences in the stress response","volume":"1731","author":"Grafe","year":"2020","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.dadr.2024.100304_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.smrv.2011.03.004","article-title":"Circadian rhythms, sleep, and substance abuse","volume":"16","author":"Hasler","year":"2012","journal-title":"Sleep. Med Rev."},{"key":"10.1016\/j.dadr.2024.100304_bib14","article-title":"Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: a systematic review","volume":"237","author":"Huhn","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"650","key":"10.1016\/j.dadr.2024.100304_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8238","article-title":"Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper","volume":"14","author":"Huhn","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.dadr.2024.100304_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109685","article-title":"Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement","volume":"239","author":"Illenberger","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.dadr.2024.100304_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.666945","article-title":"Safety and preliminary efficacy of lorcaserin for cocaine use disorder: a phase I randomized clinical trial","volume":"12","author":"Johns","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"9","key":"10.1016\/j.dadr.2024.100304_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.dadr.2024.100304_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz016","article-title":"Sleep deprivation differentially affects subcomponents of cognitive control","volume":"42","author":"Kusztor","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.dadr.2024.100304_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.905332","article-title":"Sex specific sleep parameters among people with substance use disorder","volume":"13","author":"Martin","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.dadr.2024.100304_bib21","article-title":"Understanding the role of orexin neuropeptides in drug addiction: preclinical studies and translational value","volume":"15","author":"Matzeu","year":"2021","journal-title":"Front Behav. Neurosci."},{"key":"10.1016\/j.dadr.2024.100304_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112434","article-title":"Suvorexant enhances oxycodone-induced respiratory depression in male rats","volume":"264","author":"Moreira-Junior","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2024.100304_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/NSS.S272176","article-title":"Deciphering age differences in experience-based decision-making: the role of sleep","volume":"12","author":"Peng","year":"2020","journal-title":"Nat. Sci. Sleep."},{"issue":"12","key":"10.1016\/j.dadr.2024.100304_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2024.100304_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.sleep.2022.01.024","article-title":"Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder","volume":"90","author":"Roth","year":"2022","journal-title":"Sleep. Med"},{"key":"10.1016\/j.dadr.2024.100304_bib26","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.dadr.2024.100304_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11920-018-0940-9","article-title":"Sex differences in Insomnia: from epidemiology and etiology to intervention","volume":"20","author":"Suh","year":"2018","journal-title":"Curr. Psychiatry Rep."},{"issue":"01","key":"10.1016\/j.dadr.2024.100304_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J. Clin. Sleep. Med."},{"issue":"1","key":"10.1016\/j.dadr.2024.100304_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41386-019-0465-x","article-title":"Drugs, sleep, and the addicted brain","volume":"45","author":"Valentino","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.dadr.2024.100304_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.sleep.2021.05.021","article-title":"A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem","volume":"84","author":"Wilkerson","year":"2021","journal-title":"Sleep. Med"},{"key":"10.1016\/j.dadr.2024.100304_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep. Med"},{"key":"10.1016\/j.dadr.2024.100304_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.11.023","article-title":"The potential role of the orexin reward system in future treatments for opioid drug abuse","volume":"1731","author":"Zarrabian","year":"2020","journal-title":"Brain Res."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277272462400088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277272462400088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T22:33:10Z","timestamp":1747693990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277272462400088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S277272462400088X"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100304","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b\/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100304"}}